Invesco’s CASI Pharmaceuticals CASI Stock Holding History

Invesco’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,445	Closed	-$35K	–	3971
2021 Q1	$35K	Buy	1,445 +265	+22%	+$7.44K	﹤0.01%	3842
2020 Q4	$35K	Buy	+1,180	New	+$25.6K	﹤0.01%	3753
2019 Q1	–	Sell	-1,330	Closed	-$53K	–	3714
2018 Q4	$53K	Buy	1,330 +161	+14%	+$6.1K	﹤0.01%	3688
2018 Q3	$55K	Sell	1,169 -187	-14%	-$13.1K	﹤0.01%	3813
2018 Q2	$112K	Buy	+1,356	New	+$91.5K	﹤0.01%	3766

Other funds holding CASI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Invesco's CASI Position: Q2 2021 in Review

Invesco sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 1,445 shares — an estimated $35K sold.

Invesco first reported a position in CASI in Q2 2018 and held it in 5 quarters. The position peaked at $112K in Q2 2018. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

Invesco reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Invesco sold 1,445 CASI Pharmaceuticals shares in Q2 2021, an estimated $35K.
Invesco first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Invesco's CASI Pharmaceuticals position peaked at $112K in Q2 2018.
68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.